Some clinical morphological and molecular genetic aspects in patients with clinical signs of hereditary breast cancer

Abstract

Aim. To study the clinical morphological and molecular genetic characteristics of clinically hereditary breast cancer with and without verified mutation of BRCA1, BRCA2 compared to sporadic breast cancer.

Methods. The study included 191 female patients with verified breast cancer stage I-IIA and clinical signs of hereditary breast cancer. In order to identify mutations in genes ВRCA1/2 molecular genetic analysis of deoxyribonucleic acid from peripheral blood leukocytes was performed.

Results. The total frequency of mutations in the genes BRCA1 and ВRCA2 amounted 14.1% of the total number of examined patients. The most common mutation in clinically hereditary breast cancer among residents of the Rostov Region was 5382insC in BRCA1 gene, which corresponds to the nationwide data. Also common features of hereditary breast cancer compared to sporadic breast cancer were identified: young age at the time of disease manifestation, high prevalence of triple-negative cancer, history of infertility, increased level of p53 and androgen receptor expression, decreased level of aneuploid cell and proliferation index in the tumor.

Conclusion. In a number of clinical morphological and molecular genetic parameters, clinically hereditary breast cancer differs from sporadic breast cancer. These indicators in the future can be used as criteria for selection of patients with clinically hereditary breast cancer without confirmed BRCA1/2 mutation by standard panels for in-depth genetic testing.

Keywords

BRCA1 / BRCA2 / clinically hereditary breast cancer / BRCA1 / BRCA2

References

[1] Davydov M.I., Aksel’ E.M. Statistika zlokachestvennykh novoobrazovaniy v Rossii i stranakh SNG v 2012 g. (Statistics of malignant neoplasms in Russia and CIS countries in 2012.) Moscow: Izdatel'skaya gruppa RONTs. 2014; 226 p. (In Russ.)

[2] Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. М.: Издательская группа РОНЦ. 2014; 226 с.

[3] Semiglazov V.F., Merabishvili V.M., Semiglazov V.V. et al. Epidemiology and screening for breast cancer. Voprosy oncologii. 2017; 63 (3): 375–384. (In Russ.)

[4] Семиглазов В.Ф., Мерабишвили В.М., Семиглазов В.В. и др. Эпидемиология и скрининг рака молочной железы. Вопр. онкол. 2017; 63 (3): 375-384.

[5] Imyanitov E.N. General knowledge about hereditary cancer syndromes. Practicheskaya oncologiya. 2014; 15 (3): 101–106. (In Russ.)

[6] Имянитов Е.Н. Общие представления о наследственных опухолевых синдромах. Практич. онкол. 2014; 15 (3): 101-106.

[7] Imyanitov E.N. Biology of breast cancer. Practicheskaya oncologiya. 2017; 18 (3): 221–231. (In Russ.)

[8] Имянитов Е.Н. Биология рака молочной железы. Практич. онкол. 2017; 18 (3): 221-231.

[9] Bit-Sava E.M., Yegorenkov V.V., Damenia A.O. et al. New approaches to breast cancer surgery. Practicheskaya oncologiya. 2017; 18 (3): 232–245. (In Russ.)

[10] Бит-Сава Е.М., Егоренков В.В., Дамениа А.О. и др. Новые подходы в хирургии рака молочной железы. Практич. онкол. 2017; 18 (3): 232-245.

[11] Hung-Wen Lai, Shou-Tung Chen, Dar-Ren Chen et al. Current trends in and indications for endoscopy-assisted breast surgery for breast cancer: Results from a six-year study conducted by the Taiwan Endoscopic Breast Surgery Cooperative Group. PLoS ONE. 2017; 11 (3): e0150310. DOI: 10.1371/journal.pone.015031.

[12] Vodolazhskiy D.I., Shatova Y.S., Komo­va E.A., Dvadnenko K.V. BRCA mutations among the patients with clinically hereditary breast cancer in the South Federal state. Sovremennye problemy nauki i obrazovaniya . 2015; (3). (In Russ.)

[13] Водолажский Д.И., Шатова Ю.С., Комова Е.А., Двадненко К.В. Частота встречаемости ВRCA-мутаций в Южном Федеральном округе у больных с клиническими признаками наследственного рака молочной железы. Соврем. пробл. науки и образования. 2015; (3).

[14] Khodorovich O.C., Snigireva G.P., Chkhikvadze V.D. et al. BRCA-associated breast cancer. A case from practice. Trudnyy patsient. 2016; 14 (10–11): 46–48. (In Russ.)

[15] Ходорович О.С., Снигирёва Г.П., Чхиквадзе В.Д. и др. BRCA-ассоциированный рак молочной железы. Случай из практики. Трудный пациент. 2016; 14 (10-11): 46-48.

[16] Kit O.I., Shatova Y.S., Novikova I.A. et al. Expression of p53 and BCL2 in various subtypes of breast cancer. Fundamental’nye issledovaniya. 2014; (10): 85–88. (In Russ.)

[17] Кит О.И., Шатова Ю.С., Новикова И.А. и др. Экспрессия p53 и BCL2 при различных подтипах рака молочной железы. Фундаментал. исслед. 2014; (10): 85-88.

[18] Shatova Y.S., Vashchenko L.N., Novikova I.A. et al. Expression of topoisomerase-2Α and E-cadherin in different breast cancer subtypes and reproductive status of patients. Sovremennye problemy nauki i obrazovaniya. 2015; (3): 156. (In Russ.)

[19] Шатова Ю.С., Ващенко Л.Н., Новикова И.А. и др. Экспрессия топоизомеразы-2Α и Е-кадгерина при различных подтипах рака молочной железы и репродуктивном статусе больных. Соврем. пробл. науки и образования. 2015; (3): 156.

[20] Brozek I., Cybulska C., Ratajska M. et al. Prevalence of the most frequent BRCA1 mutations in Polish population. J. Applied Genetics. 2011; (52): 325–330. DOI: 10.1007/s13353-011-0040-6.

[21] Brozek I., Cybulska C., Ratajska M. et al. Prevalence of the most frequent BRCA1 mutations in Polish population. J. Applied Genetics. 2011; (52): 325-330. DOI: 10.1007/s13353-011-0040-6.

[22] Kogan M.I., Chibichan M.B., Vodolazhskiy D.I. et al. Expression of genetic loci in mononuclear fraction of peripheral blood of patients with prostate cancer. Onkourologiya. 2012: (4) 40–48. (In Russ.)

[23] Коган М.И., Чибичан М.Б., Водолажский Д.И. и др. Экспрессия генетических локусов в мононуклеарной фракции периферической крови больных раком предстательной железы. Онкоурология. 2012; (4) 40-48.

[24] Kornienko I.V., Vodolazhskiy D.I. Patterns of occurrence of single nucleotide substitutions in the hypervariable parts of the control region of human mitochondrial DNA. Moleculyarnaya biologiya. 2010; 44 (3): 439–446. (In Russ.)

[25] Корниенко И.В., Водолажский Д.И. Закономерности появления одиночных нуклеотидных замен в гипервариабельных участках контрольного региона митохондриальной ДНК человека. Молекулярн. биол. 2010; 44 (3): 439-446.

[26] Novikova I.A., Shatova Y.S., Zlatnik E.Y. et al. Proliferative and immunological characteristics of molecular-biological subtypes of breast cancer. Mezhdunarodnyy zhurnal prikladnykh i fundamental'nykh issledovaniy. 2014; (11): 116–119. (In Russ.)

[27] Новикова И.А., Шатова Ю.С., Златник Е.Ю. и др. Пролиферативные и иммунологические характеристики молекулярно-биологических подтипов рака молочной железы. Международ. ж. прикладных и фундаментал. исслед. 2014; (11): 116-119.

[28] Lüftner D., Henschke P., Flath B. et al. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. Anticancer Res. 2004; 24 (2B): 895–906. PMID: 15161043.

[29] Lüftner D., Henschke P., Flath B. et al. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. Anticancer Res. 2004; 24 (2B): 895-906. PMID: 15161043.

RIGHTS & PERMISSIONS

Shatova Y.S., Chebotareva E.A., Zlatnik E.Y., Novikova I.A., Vodolazhskiy D.I., Dzhenkova E.A.